In a different fashion, rapalogs that inhibit mTOR (e.g., rapamycin and its derivatives, everolimus, and temsirolimus) exhibit anti-tumor effects by targeting PI3K/Akt/mTOR axis and cell proliferation. Here, MTOR is linked to neoplasm.